Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today highlighted newly published independent preclinical research evaluating the effects of PV-10 in a clinically ...

Biopharmaceuticals, also known as biologics, are a class of medicines produced using living systems such as microorganisms, plant or animal cells, or recombinant DNA technology. Unlike traditional ...

View Day One Biopharmaceuticals, Inc. DAWN stock quote prices, financial information, real-time forecasts, and company news from CNN.

Protein-based medicines are increasingly prevalent as a crucial category of contemporary therapeutics. The presence of ...

Even trace amounts can compromise biological products, causing adverse reactions and regulatory headaches. Endotoxin-free recombinant proteins are the solution. What Are the Potential Risks of ...

Preclinical research on Caliway's fat reduction drug candidate CBL-514 in combination with GLP-1R-based weight-loss therapies has been selected for presentation at the American Diabetes Association's ...

Management projected full-year 2025 net product revenues of $140 million to $150 million for OJEMDA, citing "strong and persistent demand, deepening prescriber adoption, and consistent payer coverage" ...

Day One Biopharmaceuticals (DAWN) has drawn investor attention after strong recent share performance, with returns of 65% over the past week and 81% over the past month, prompting closer review of its ...

NIJMEGEN, The Netherlands--(BUSINESS WIRE)--Synthon Biopharmaceuticals B.V., a biopharmaceutical research and development company creating innovative precision medicines for patients with relentless ...

The tremendous potential of the emerging class of medicines known as biotherapeutics — medicines produced from living cells — is exciting new terrain for researchers, industry and health care ...

Day One Biopharmaceuticals, Inc. (DAWN) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.69 per share a year ago.